| __timestamp | HUTCHMED (China) Limited | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 72429000 |
| Thursday, January 1, 2015 | 29829000 | 78634000 |
| Friday, January 1, 2016 | 39578000 | 75374000 |
| Sunday, January 1, 2017 | 43277000 | 92157000 |
| Monday, January 1, 2018 | 48645000 | 93326000 |
| Tuesday, January 1, 2019 | 52934000 | 103132000 |
| Wednesday, January 1, 2020 | 61349000 | 110171000 |
| Friday, January 1, 2021 | 127125000 | 218817000 |
| Saturday, January 1, 2022 | 136106000 | 233827000 |
| Sunday, January 1, 2023 | 133175999 | 267194000 |
Unleashing insights
In the ever-evolving landscape of healthcare, operational efficiency is paramount. Over the past decade, Lantheus Holdings, Inc. and HUTCHMED (China) Limited have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Lantheus Holdings saw a remarkable 270% increase in SG&A expenses, peaking at approximately $267 million in 2023. This growth reflects the company's aggressive expansion and strategic investments in operational capabilities.
Conversely, HUTCHMED's SG&A expenses grew by nearly 400% over the same period, reaching around $133 million in 2023. This surge underscores HUTCHMED's commitment to scaling its operations and enhancing its market presence.
These trends highlight the dynamic nature of the healthcare sector, where strategic investments in operational costs can significantly impact a company's competitive edge.
Novo Nordisk A/S or Lantheus Holdings, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Soleno Therapeutics, Inc.
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights